RxDoctor Payments Data

Amy Shirer, MD

Family Medicine · Reedley, CANPI 1598085524

Payments from drug & device makers

$4,503in general payments, 2019–2025

Across 259 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$585
  • Lilly USA, LLC$535
  • GSK$516
  • Takeda Pharmaceuticals U.S.A., Inc.$397
  • Novo Nordisk$390
  • AbbVie$299
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,503100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,503 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$86,777
Medicare patients
292
Services billed
914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter99$83,683
JardianceEmpagliflozin62$70,710
OzempicSemaglutide66$69,346
FarxigaDapagliflozin Propanediol57$56,670
EliquisApixaban51$51,874
MounjaroTirzepatide30$48,632
TrulicityDulaglutide36$45,519
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$17,570
VraylarCariprazine Hcl11$14,892
Tresiba Flextouch U-200Insulin Degludec18$11,130
LinzessLinaclotide12$9,697
Breo ElliptaFluticasone/Vilanterol15$9,681
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$8,870
MyrbetriqMirabegron14$8,729
XareltoRivaroxaban12$8,675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$516$100,184126 claims
Lilly USA, LLCMounjaro, Trulicity$535$94,15166 claims
AstraZenecaFarxiga, Breztri Aerosphere$585$74,24077 claims
Boehringer IngelheimJardiance$161$70,71062 claims
Novo NordiskOzempic$390$69,34666 claims
PfizerEliquis$253$51,87451 claims
AbbVieVraylar, Linzess, Synthroid$299$31,148120 claims
Astellas Pharma US IncMyrbetriq$73$8,72914 claims
Johnson & JohnsonXarelto$84$8,67512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Reedley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →